DE69921966D1 - Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen - Google Patents

Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen

Info

Publication number
DE69921966D1
DE69921966D1 DE69921966T DE69921966T DE69921966D1 DE 69921966 D1 DE69921966 D1 DE 69921966D1 DE 69921966 T DE69921966 T DE 69921966T DE 69921966 T DE69921966 T DE 69921966T DE 69921966 D1 DE69921966 D1 DE 69921966D1
Authority
DE
Germany
Prior art keywords
cytostatics
epothilones
fermentative production
crystal shapes
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69921966T
Other languages
English (en)
Other versions
DE69921966T2 (de
Inventor
Hans Hofmann
Marion Mahnke
Klaus Memmert
Frank Petersen
Thomas Schupp
Ernst Kuesters
Michael Mutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69921966D1 publication Critical patent/DE69921966D1/de
Application granted granted Critical
Publication of DE69921966T2 publication Critical patent/DE69921966T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
DE69921966T 1998-02-19 1999-02-17 Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen Expired - Lifetime DE69921966T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH39698 1998-02-19
CH39698 1998-02-19
CH100798 1998-05-05
CH100798 1998-05-05
PCT/EP1999/001025 WO1999042602A2 (en) 1998-02-19 1999-02-17 Fermentative preparation process for cytostatics and crystal forms thereof

Publications (2)

Publication Number Publication Date
DE69921966D1 true DE69921966D1 (de) 2004-12-23
DE69921966T2 DE69921966T2 (de) 2005-11-03

Family

ID=25684443

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69921966T Expired - Lifetime DE69921966T2 (de) 1998-02-19 1999-02-17 Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen

Country Status (25)

Country Link
US (8) US6194181B1 (de)
EP (2) EP1428826A3 (de)
JP (3) JP3681109B2 (de)
KR (4) KR100595774B1 (de)
CN (2) CN1229502C (de)
AT (1) ATE282710T1 (de)
AU (1) AU746294B2 (de)
BR (1) BR9908119A (de)
CA (1) CA2318818A1 (de)
CZ (1) CZ301517B6 (de)
DE (1) DE69921966T2 (de)
DK (1) DK1054994T3 (de)
ES (1) ES2233028T3 (de)
HK (1) HK1034100A1 (de)
HU (1) HU225851B1 (de)
IL (4) IL159631A0 (de)
NO (4) NO322588B1 (de)
NZ (2) NZ506138A (de)
PL (2) PL404926A1 (de)
PT (1) PT1054994E (de)
RU (1) RU2268306C2 (de)
SI (1) SI1054994T1 (de)
SK (3) SK288058B6 (de)
TR (2) TR200101634T2 (de)
WO (1) WO1999042602A2 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
KR100538095B1 (ko) * 1996-11-18 2005-12-21 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식 억제제와 식물 위생제로서의 이들의 용도
EP0977563B1 (de) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
AU2001295195B2 (en) * 2000-04-28 2007-02-01 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6998256B2 (en) * 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US6989450B2 (en) 2000-10-13 2006-01-24 The University Of Mississippi Synthesis of epothilones and related analogs
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
SK8552003A3 (en) * 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
PT1353668E (pt) 2001-01-25 2008-06-30 Bristol Myers Squibb Co Processos de preparação de substâncias farmacêutica contendo substâncias análogas à epotilona para o tratamento de cancro
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1368030A1 (de) 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilon-derivative zur behandlung von refraktären tumoren
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
SK11082003A3 (sk) 2001-03-14 2004-08-03 Bristol-Myers Squibb Company Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení
MXPA03010909A (es) * 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
EP2030618A3 (de) 2002-01-14 2009-03-11 Novartis AG Kombinationen enthaltend Epothilone und Antimetaboliten
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
WO2003074521A1 (en) * 2002-03-01 2003-09-12 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
DE60328772D1 (de) * 2002-05-01 2009-09-24 Novartis Ag Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
EP1575556A2 (de) * 2002-05-20 2005-09-21 Kosan Biosciences, Inc. Verfahren zur verabreichung von epothilon d
AU2003243561A1 (en) * 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1767535B1 (de) 2002-08-23 2009-12-02 Sloan-Kettering Institute For Cancer Research Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
KR100606016B1 (ko) * 2002-09-13 2006-07-26 삼성전자주식회사 이동 통신시스템에서 양방향 데이터 서비스 제공 방법
KR101406635B1 (ko) * 2002-09-23 2014-06-11 브리스톨-마이어스 스큅 컴퍼니 에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의 ｘ-선 결정 구조
JP2006504743A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
CN1867343A (zh) * 2003-10-09 2006-11-22 高山生物科学股份有限公司 治疗制剂
EP1670487A4 (de) * 2003-10-09 2008-05-21 Kosan Biosciences Inc Therapeutische formulierungen
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
BRPI0616755A2 (pt) 2005-09-27 2011-06-28 Novartis Ag compostos de carboxiamina e métodos de uso dos mesmos
CN1312286C (zh) * 2005-10-19 2007-04-25 华南理工大学 一种利用纤维堆囊菌高效生产埃博霉素的方法
AU2006314444C1 (en) 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
EP2314297A1 (de) 2006-04-05 2011-04-27 Novartis AG Kombinationen aus bcr-abl/c-kit/pdgf-r tk-Hemmern zu Krebsbehandlung
CN102671196B (zh) 2006-04-05 2014-12-03 诺华股份有限公司 用于治疗癌症的治疗剂的组合
KR20090007635A (ko) 2006-05-09 2009-01-19 노파르티스 아게 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
CL2007002362A1 (es) * 2006-08-16 2008-08-08 Novartis Ag Forma de cristal de la epotilona b; composicion farmaceutica que la comprende; y uso para el tratamiento de una enfermedad proliferativa, tal como un tumor.
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
EP2359818A1 (de) 2007-02-15 2011-08-24 Novartis AG Kombinationen von LB589 mit HSP 90 Inhibitoren zur Krebsbehandlung
US8906947B2 (en) 2008-02-01 2014-12-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Method for the separation and purification of epothilones
MX2010010525A (es) 2008-03-24 2010-10-25 Novartis Ag Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida.
NZ588069A (en) 2008-03-26 2012-06-29 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
DK2370076T3 (en) * 2008-11-28 2017-04-03 Novartis Ag Pharmaceutical combination comprising an Hsp 90 inhibitor and an mTOR inhibitor
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
EP2391366B1 (de) 2009-01-29 2012-11-28 Novartis AG Substituierte benzimidazole zur behandlung von astrozytomen
SI2445903T1 (sl) 2009-06-26 2014-07-31 Novartis Ag 1,3-disubstituirani imidazolidin-2-onski derivati kot inhibitorji CYP 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
MY156209A (en) 2009-11-04 2016-01-29 Novartis Ag Heterocyclic sulfonamide derivatives useful mek inhibitors
CA2781218A1 (en) 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2571525A4 (de) 2010-05-18 2016-04-27 Cerulean Pharma Inc Zusammensetzungen und verfahren zur behandlung von autoimmun- und anderen erkrankungen
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
IN2014DN00123A (de) 2011-06-09 2015-05-22 Novartis Ag
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
KR20140025530A (ko) 2011-06-27 2014-03-04 노파르티스 아게 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
EA025322B1 (ru) 2011-12-22 2016-12-30 Новартис Аг Производные дигидробензооксазина и дигидропиридооксазина
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
JP2015503515A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物および組成物
EP2794591A1 (de) 2011-12-23 2014-10-29 Novartis AG Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
CN104125953A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013096055A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
WO2013171640A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013171642A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PL2900637T3 (pl) 2012-05-15 2018-01-31 Novartis Ag Pirymidyna podstawiona tiazolem lub imidazolem, amidowe pochodne pirazyny i pirydyny i powiązane związki takie jak inhibitory abl1, abl2 i bcr-abl1 do leczenia nowotworu, specyficznych infekcji wirusowych i specyficznych zaburzeń cns
CU24265B1 (es) 2012-05-15 2017-07-04 Novartis Ag Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
EP2861256B1 (de) 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Zusammensetzungen zur behandlung von krebs und verfahren zur herstellung davon
PE20150998A1 (es) 2012-10-02 2015-06-29 Epitherapeutics Aps Inhibidores de histona demetilasas
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
CN103910742B (zh) * 2013-01-07 2016-07-13 浙江海正药业股份有限公司 一种制备埃博霉素b无定形粉末的方法
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2948451B1 (de) 2013-01-22 2017-07-12 Novartis AG Substituierte purinonverbindungen
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
PL2961736T3 (pl) 2013-02-27 2018-08-31 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
CN103275098B (zh) * 2013-06-07 2015-07-08 江苏迪沃特仪器设备科技有限公司 用动态轴向压缩柱分离纯化埃博霉素的方法
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
JP6517319B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
WO2015153498A1 (en) 2014-03-31 2015-10-08 Epitherapeutics, Aps Inhibitors of histone demethylases
BR112016022499A2 (pt) 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
AU2015306662A1 (en) 2014-08-27 2017-03-09 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases
EP3347097B1 (de) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
EP3710006A4 (de) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Substituierte heteroarylverbindungen und verfahren zur verwendung
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
FR3087650B1 (fr) 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58179496A (ja) 1982-04-12 1983-10-20 Takeda Chem Ind Ltd ランカシジンの改良製造法
EP0094157B1 (de) 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmazeutische Zusammensetzung und ihre Verwendung
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3317064A1 (de) 1983-05-10 1984-11-15 Consortium für elektrochemische Industrie GmbH, 8000 München Verfahren zur herstellung von cyclooctaamylose
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
EP0216731B1 (de) * 1985-09-13 1990-03-14 Gesellschaft für Biotechnologische Forschung mbH (GBF) Makrozyklische Antibiotika
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
NZ224497A (en) 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
DK0465535T3 (da) 1989-04-03 1999-03-01 Janssen Pharmaceutica Nv Regioselektive substitutioner i cyclodextriner
GB8910069D0 (en) 1989-05-03 1989-06-21 Janssen Pharmaceutica Nv Method of topically treating acne vulgaris
DE69033926T2 (de) 1989-11-22 2002-10-24 Janssen Pharmaceutica Nv Verwendung von Piperazin-Acetamid-Derivaten gegen Reperfusionsschaden
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
IL100856A (en) 1991-02-15 1998-03-10 Janssen Pharmaceutica Nv History of carboxyl (alkyloxyalkyl of cyclodextrins, their preparation and pharmaceutical preparations containing them
CA2061891A1 (en) 1991-03-08 1992-09-09 Robert F. Van Ginckel Flunarizine containing anti-neoplastic compositions
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4207092A1 (de) * 1992-03-06 1993-09-16 Schott Glaswerke Endoskop
DE4207922A1 (de) 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
RU2127733C1 (ru) 1992-03-18 1999-03-20 Жансен Фармасетика Н.В. Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и фармацевтическая композиция на их основе
IL105553A (en) 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage forms consisting of a porous network of matrix that releases a substance that dissipates rapidly in water
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5395951A (en) * 1992-11-17 1995-03-07 Council Of Scientific & Industrial Research Triterpene derivatives of azadirachtin having insect antifeedant and growth inhibitory activity and a process for extracting such compounds from the neem plant
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
PH31594A (en) 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
AU3846395A (en) 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
BR9611562A (pt) 1995-11-23 1999-03-02 Janssen Pharmaceutica Nv Misturas sólidas de ciclodextrinas preparadas via extrusão sob fusão
JP3865436B2 (ja) 1996-07-11 2007-01-10 塩水港精糖株式会社 分岐シクロデキストリンの製造方法
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
KR100538095B1 (ko) 1996-11-18 2005-12-21 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식 억제제와 식물 위생제로서의 이들의 용도
EP0977563B1 (de) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1847540A1 (de) 1997-08-09 2007-10-24 Bayer Schering Pharma Aktiengesellschaft Neue Epothilonderivate, Herstellungsverfahren dafür und ihre pharmazeutische Verwendung
US6242489B1 (en) * 1997-09-25 2001-06-05 Ecological Technologies Corporation Malodorant compositions
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
IL144501A0 (en) * 1999-02-22 2002-05-23 Biotechnolog Forschung Gmbh Epothilone derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
US6291684B1 (en) * 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
GB0230024D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SK286517B6 (sk) 2008-12-05
IL137691A (en) 2007-12-03
EP1054994A4 (de) 2001-06-19
US20090326239A1 (en) 2009-12-31
KR20010041068A (ko) 2001-05-15
ATE282710T1 (de) 2004-12-15
SK287677B6 (sk) 2011-05-06
NO322588B1 (no) 2006-10-30
TR200002431T2 (tr) 2001-01-22
KR20070058021A (ko) 2007-06-07
DK1054994T3 (da) 2005-03-14
JP3681109B2 (ja) 2005-08-10
JP2002504346A (ja) 2002-02-12
CN1286839C (zh) 2006-11-29
US20020165256A1 (en) 2002-11-07
EP1428826A2 (de) 2004-06-16
US6656711B2 (en) 2003-12-02
EP1428826A3 (de) 2004-10-27
KR100873526B1 (ko) 2008-12-11
JP2005068156A (ja) 2005-03-17
HK1034100A1 (en) 2001-10-12
PT1054994E (pt) 2005-04-29
IL137691A0 (en) 2001-10-31
NZ525622A (en) 2004-10-29
US6380227B1 (en) 2002-04-30
CZ301517B6 (cs) 2010-03-31
HUP0100855A2 (hu) 2001-06-28
HU225851B1 (en) 2007-11-28
IL159631A (en) 2007-07-04
SI1054994T1 (en) 2005-06-30
CZ20002994A3 (cs) 2000-11-15
PL404926A1 (pl) 2013-12-09
NO20004114D0 (no) 2000-08-17
PL342423A1 (en) 2001-06-04
EP1054994B1 (de) 2004-11-17
NO20052034L (no) 2000-10-17
US20030194787A1 (en) 2003-10-16
NO20061735L (no) 1999-08-20
JP2010099089A (ja) 2010-05-06
WO1999042602A3 (en) 1999-11-25
TR200101634T2 (tr) 2002-06-21
PL196787B1 (pl) 2008-01-31
US20040142990A1 (en) 2004-07-22
NO20061736L (no) 1999-08-20
EP1054994A2 (de) 2000-11-29
KR20080070781A (ko) 2008-07-30
IL159631A0 (en) 2004-06-01
NO329063B1 (no) 2010-08-09
NO321596B1 (no) 2006-06-06
NO20004114L (no) 2000-10-17
RU2268306C2 (ru) 2006-01-20
AU3028799A (en) 1999-09-06
HUP0100855A3 (en) 2005-05-30
US20030220379A1 (en) 2003-11-27
CA2318818A1 (en) 1999-08-26
KR100595774B1 (ko) 2006-07-03
US7101702B2 (en) 2006-09-05
ES2233028T3 (es) 2005-06-01
SK288058B6 (sk) 2013-03-01
CN1291239A (zh) 2001-04-11
BR9908119A (pt) 2000-10-24
US20070197611A1 (en) 2007-08-23
US6194181B1 (en) 2001-02-27
KR20060032222A (ko) 2006-04-14
SK12402000A3 (sk) 2001-05-10
AU746294B2 (en) 2002-04-18
CN1229502C (zh) 2005-11-30
NZ506138A (en) 2003-07-25
DE69921966T2 (de) 2005-11-03
WO1999042602A2 (en) 1999-08-26
CN1535971A (zh) 2004-10-13

Similar Documents

Publication Publication Date Title
DE69921966D1 (de) Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen
ATE426021T1 (de) Verfahren zur herstellung von biopterinen
DE69939901D1 (de) Verfahren und materialien zur herstellung von glucosamin
ATE313619T1 (de) Bioreaktor für die kultivierung von mikroorganismen sowie verfahren zur herstellung desselben
DE69329154T2 (de) Erhöhte produktion von taxol und taxanen mittels -taxus-spezifische zellkulturen
DE69637656D1 (de) Methoden zur Züchtung von Tierzellen
DK88586A (da) Fremgangsmaade til fremstilling af l-carnitin ad mikrobiologisk vej
ATE365809T1 (de) Verfahren zur herstellung eines kulturmediums aus erneuerbarem rohmaterial
DE60105435D1 (de) Verfahren zur herstellung von beta-karotin
ATE274597T1 (de) Verfahren zur herstellung und rückgewinnung von erythritol aus kulturmedium
ATE220714T1 (de) Verfahren zur herstellung von proteinen
DE60207914D1 (de) Verfahren zur Herstellung von L-Glutaminsäure
DE60307403D1 (de) Bakterien und Verfahren zur Herstellung von Riboflavin durch Fermentation
ATE174966T1 (de) Verfahren zur herstellung von biotin
ATE386838T1 (de) Pflanzennährlösung aus einem wiedergewonnenem filtrat aus pflanzenfaser-biopulp sowie herstellungsverfahren
ATE355359T1 (de) Selektionsmedia für beauveriolid i oder iii und verfahren zur selektiven herstellung dieser substanzen
ATE191508T1 (de) Mikrobiologisches verfahren zur herstellung von 1-ungesättigten, 17-beta-carboxysubstituierten 3- oxo-4-azaandrostan-3-onen
EP0939133A3 (de) Verfahren zur Herstellung von Polyol durch Recyclisierung von Mikroorganismen
DE3884922T2 (de) Verfahren zur Herstellung von thermostabilen alpha-Amylasen durch Kultivierung von überproduzierenden Mikroorganismen.
DE60323649D1 (de) Methode zur Herstellung von Neuronen aus Stammzellen und Medium zur Kultur von Stammzellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN